Astrazeneca plc

Research Astrazeneca plc (AZN) on Bullrun: valuation model: 28.4% overvalued, market cap USD 296.13B, P/E 57.3, dividend yield 1.7%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerAZN
• ExchangeNASDAQ
• CountryUnited Kingdom
• SectorHealthcare
• IndustryDrug Manufacturers-General
• CurrencyUSD
• Valuation signal28.4% overvalued
• Market capUSD 296.13B
• P/E57.3
• Dividend yield1.7%
• Financial periodQ1 2026
• RevenueUSD 15.29B
• Net incomeUSD 3.08B
• Free cash flowUSD 1.82B
• Gross margin82.5%

Valuation Snapshot

Bullrun's latest valuation model marks Astrazeneca plc as 28.4% overvalued; latest market cap is USD 296.13B; P/E is 57.3; dividend yield is 1.7%.

About Astrazeneca plc

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.

Frequently asked questions

Is Astrazeneca plc overvalued or undervalued?

Bullrun's valuation model currently marks Astrazeneca plc as 28.4% overvalued.

What is Astrazeneca plc's market cap?

Astrazeneca plc's market capitalization is USD 296.13B.

What is Astrazeneca plc's P/E ratio?

Astrazeneca plc's price-to-earnings (P/E) ratio is 57.3.

Does Astrazeneca plc pay a dividend?

Astrazeneca plc has a dividend yield of 1.7%.

What does Astrazeneca plc do?

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.